StayinFront, Inc. and AMAG Pharmaceuticals, Inc. Sign Agreement for Customer Relationship Management Application
| Source: StayinFront
FAIRFIELD, NJ--(Marketwire - May 30, 2008) - StayinFront, Inc., a global provider of
enterprise-wide customer relationship management (CRM) applications,
decision support tools, data services and eBusiness systems, today
announced that it has signed an agreement with AMAG Pharmaceuticals, Inc.
to deliver its industry-centric CRM solution known as StayinFront Pharma.
AMAG will deploy StayinFront's flagship product, StayinFront Pharma 10, for
its U.S. field sales representatives.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its
proprietary nanoparticle technology for the development and
commercialization of therapeutic iron compounds to treat anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease.
"We are looking forward to a long term relationship with AMAG and we are
confident that our system will enhance their efforts to successfully track
sales activities in the U.S.," said Ken Arbadji, vice president of Sales,
StayinFront.
About StayinFront
StayinFront, Inc. is a leading global provider of enterprise-wide customer
relationship management (CRM) applications, decision support tools, data
services, sample inventory management solutions and eBusiness systems.
StayinFront offers rapidly configured and implemented solutions and
services to manage and integrate all points of customer interaction
including sales, marketing and customer support.
StayinFront has been chosen globally as a strategic CRM partner by many of
the world's top life sciences, consumer goods, financial services and
business-to-business companies, and StayinFront solutions have been
implemented in over 20 countries in 12 languages.
StayinFront's flexible product architecture, object-oriented data modeling
and range of deployment options provide an "exact fit" solution to help
drive business processes, better manage the administrative functions of the
system and lower ongoing costs of ownership.
StayinFront also offers a range of support services, including StayinFront
Data Quality Services, to improve, standardize, augment and further
leverage the informational assets contained in proprietary databases.
Headquartered in Fairfield, New Jersey, StayinFront has offices in
Illinois, the United Kingdom, Ireland, India, Australia, Singapore and New
Zealand. For more information, visit www.stayinfront.com.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its
proprietary nanoparticle technology for the development and
commercialization of therapeutic iron compounds to treat anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease.
Ferumoxytol, the Company's key product candidate, is being developed for
use as an intravenous iron replacement therapeutic agent for the treatment
of iron deficiency anemia in chronic kidney disease patients. The Company
has released data on all four planned Phase III clinical trials of
ferumoxytol as an intravenous iron replacement therapeutic agent in chronic
kidney disease patients. The Company submitted a New Drug Application for
marketing approval of ferumoxytol with the U.S. Food and Drug
Administration (FDA) in December 2007, which was accepted for filing by the
FDA in February 2008.